Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.67 |
| ▸ | CA1 | P00915 | 13/20 | 0.67 |
| ▸ | CA9 | Q16790 | 4/20 | 0.67 |
| ▸ | CA6 | P23280 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335715 | 1.00 | CA2 (0.67) | CA2CA1CA9CA6CA12 | |
| SCHEMBL11840111 | 0.82 | HTR6 (0.77) | CA2CA1CA9CA6CA12 | |
| SCHEMBL12160510 | 0.82 | CDK2 (0.58) | CA2CA1CA9CA6CA12 | |
| SCHEMBL2634765 | 0.80 | HTR6 (0.62) | CA2CA1CA9CA6CA12 | |
| SCHEMBL31060499 | 0.80 | CA2 (1.00) | CA2CA1CA9CA6CA12 | |
| SCHEMBL6957722 | 0.80 | HTR6 (0.62) | CA2CA1CA9CA6CA12 | |
| SCHEMBL1425352 | 0.80 | CA2 (1.00) | CA2CA1CA9CA6CA12 | |
| SCHEMBL1127421 | 0.79 | CA2 (0.62) | CA2CA1CA9CA6CA12 | |
| SCHEMBL3694286 | 0.78 | CA2 (0.67) | CA2CA1CA9CA6CA12 | |
| Hydrochloric Acid SCHEMBL5798932 | 0.78 | CA2 (0.96) | CA2CA1CA9CA6CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| CN-112245773-A | Dilatation balloon catheter for narrow digestive tract lesions | 浙江桐轩医疗科技有限公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| CN-105348203-B | Inhibit the composition and method of JAK approach | 里格尔药品股份有限公司 | 2018-09-18 | — | — | CN | disclosed |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-1904457-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2007044729-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006133426-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006058724-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
| US-20060100102-A1 | Toning agents for use in thermographic recording materials | AGFA-GEVAERT (BE) | 2006-05-11 | — | — | US | disclosed |
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | CA2 4750/4885CA1 4881/4885CA9 4375/4885 |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CA2 4491/4885CA1 4788/4885CA9 4302/4885 |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CA2 4491/4885CA1 4788/4885CA9 4302/4885 |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CA2 4491/4885CA1 4788/4885CA9 4302/4885 |
| US-20170298054-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CA2 4491/4885CA1 4788/4885CA9 4302/4885 |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CA2 4491/4885CA1 4788/4885CA9 4302/4885 |
| US-20060293311-A1 | e.g. 1 N2-(4-Aminosulphonylphenyl)-N4-(3-cyanomethoxy-4,5-dimethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | JAK3, JAK1, JAK2 | CA2 4238/4885CA1 3698/4885CA9 4027/4885 |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CA2 4491/4885CA1 4788/4885CA9 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.